• Cabozantinib (XL184) for Adaptive Cancer Signaling

  2026-09-09

  Cabozantinib and XL184 support more than endpoint viability assays: they enable coordinated studies of RTK signaling, angiogenesis, phosphoproteomic adaptation, and tumor-cell motility. This workflow translates acute-versus-chronic exposure findings into practical assay choices for renal cell carcinoma, medullary thyroid cancer, and endothelial models.

• β-Elemene in Adipogenesis and Metabolic Assays

  2026-09-08

  β-Elemene is a practical tool for separating lipid remodeling from nonspecific toxicity in 3T3-L1 adipogenesis and insulin-resistance experiments. This workflow connects AMPK-centered metabolic readouts with carefully controlled apoptosis, inflammation, neuroprotection, and analytical applications.

• PF-573228 FAK Inhibitor Workflow Guide

  2026-09-08

  Use PF-573228 to test how focal adhesion kinase connects matrix mechanics with dentinogenesis, cancer-cell behavior, and endothelial responses. This practical guide combines stiffness-aware controls, target-engagement assays, dosing guidance, and troubleshooting for more interpretable results.

• BFH772 (VEGFR2 inhibitor): Protocol Guide

  2026-09-07

  BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled studies of VEGFR2-mediated angiogenesis and tumor-model signaling. Its organic-solvent compatibility and water insolubility make it unsuitable for workflows requiring aqueous delivery or broad-spectrum kinase inhibition without additional formulation and selectivity controls.

• PF-573228: FAK Inhibition Beyond Stiffness

  2026-09-07

  PF-573228 is a potent FAK inhibitor for dissecting how adhesion signaling connects matrix mechanics with differentiation, cancer-cell behavior, and angiogenesis. This article translates the LAMB1–FAK–MEK1/2 dentinogenesis findings into a causal, multi-endpoint assay strategy while defining key interpretation limits.

• PX-478 2HCl: HIF-1α Workflow Guide

  2026-09-05

  PX-478 2HCl provides a titratable way to interrogate HIF-1α in normoxic and hypoxic cancer models, including radiosensitization studies and tumor-ischemia research. This guide translates its product specifications and a recent macrophage-metabolism study into practical assay design, controls, and troubleshooting decisions.

• Omeprazole (A2845): Workflow and QC Guide

  2026-09-04

  Omeprazole (A2845) is a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer mechanisms. This guide covers solvent selection, assay controls, storage, and troubleshooting; the compound is not intended for diagnostic, clinical, or therapeutic use.

• Enzalutamide, ARv7, and TNBC Metastasis

  2026-09-04

  This 2025 study connects androgen receptor variant 7 (ARv7) localization with poor outcomes in triple-negative breast cancer (TNBC) and examines how Enzalutamide and EPI-001 affect metastatic and epithelial-to-mesenchymal transition markers. Its combination of patient immunohistochemistry, TCGA-BRCA analysis, and MDA-MB-231 functional assays provides a mechanistic framework for studying androgen receptor-mediated pathway modulation beyond prostate cancer.

• DMXAA: A Mechanism-First Vascular Biology Guide

  2026-09-03

  DMXAA (Vadimezan) is more than a vascular disrupting agent: it is a useful mechanistic probe for separating endothelial collapse, VEGFR2 signaling, and tumor-cell apoptosis. This guide presents an assay-centered framework for cancer biology research and interprets a recent trafficking study without overstating pathway evidence.

• RapaLink-1: Third-Generation mTOR Inhibitor Workflows

  2026-09-03

  RapaLink-1 combines mutation-aware mTOR kinase targeting with practical workflows for glioma growth assays, cell-cycle profiling, and exploratory dormancy studies. Its strongest differentiation is a bivalent mechanism, but embryonic applications require careful validation because the reference protocol did not directly test RapaLink-1.

• Cefazedone (Refosporen): Applied Lab Workflows

  2026-09-02

  Cefazedone (Refosporen) supports structured antibacterial testing in vitro across clinically relevant Gram-positive and Gram-negative panels. This guide connects PBP-focused mechanism, broth dilution design, resistance-aware isolate selection, pharmacodynamic interpretation, and practical troubleshooting.

• EZ Cap™ OVA mRNA: Practical Delivery Workflows

  2026-09-02

  EZ Cap™ OVA mRNA combines a Cap 1 structure and poly(A) tail for controlled ovalbumin expression in immunology, airway, and vaccine development workflows. This guide translates product specifications and emerging low-inflammatory delivery research into practical setup, optimization, and troubleshooting choices.

• PX-478 2HCl: Practical HIF-1α Workflows

  2026-09-01

  PX-478 2HCl provides a small-molecule approach for testing HIF-1α-dependent metabolism, hypoxia adaptation, and radiosensitization. This workflow translates findings from macrophage and sepsis research into controlled cancer cell line hypoxia studies while clearly separating established product evidence from forward-looking assay applications.

• iPSC Cardiomyocytes for Chemical Hazard Assessment

  2026-09-01

  This study combines cardiomyocyte functional phenotypes with cytotoxicity and whole-transcriptome data to improve hazard identification and risk characterization for environmental chemicals. Its concentration-response framework shows that transcriptomic measurements can complement functional screening by adding mechanistic context and supporting biologically interpretable points of departure.

• Ridaforolimus Workflows for mTOR Cancer Research

  2026-08-31

  Build reproducible mTOR target-engagement, viability, apoptosis, and angiogenesis workflows with Ridaforolimus, also known as Deforolimus or MK-8669. The guide distinguishes direct pathway inhibition from senescence-associated phenotypes and shows how to optimize concentration, timing, controls, and interpretation.

8696 records 1/580 page Next 12345 下5页 Last page